Rethinking hair loss treatment

In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Daniel Gil, CEO, Pelage Pharmaceuticals

Francisco Ramírez-Valle, Senior Vice President, Immunology Discovery, Eli Lilly

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Poddgruvan

Rethinking hair loss treatment

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

The Golden Triangle and the gaps: Rethinking UK biotech

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

From fragile skin to living medicine: Lessons from RDEB

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Portugal, Spain and the new biotech frontier

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale